Protect your invention by filing a Provisional or Utility Patent Application using our software today! It’s easy and fully backed by patent lawyers – and you don’t have to pay until you’re done.
The Glaxo Group Limited patent solves the following problem:
Syk is a non-receptor tyrosine kinase involved in coupling activated immunoreceptors signal consuming events that mediate diverse cellular responses, including proliferation, distinction, and phagocytosis. Syk is widely expressed in hematopoietic cells. Syk inhibitor with potential anti-inflammatory and immunomodulating activities. They inhibit SYK-mediated IgG Fc epsilon and gamma receptor and BCR receptor signaling, resulting in inhibition of activation of mast cells, macrophages, and B-cells and relevant inflammatory responses and tissue damage. Mast cells play a major role in type I hypersensitivity reactions associated with urticaria, bronchial asthma, anaphylaxis and other allergic conditions. Therefore, SYK inhibitor has attracted interest from a number of therapeutic areas, including the treatment of rheumatoid arthritis, B-cell lymphoma, asthma, rhinitis and cutaneous disorders such as acute and chronic urticaria, mastocytosis, cutaneous lupus , atopic dermatitis, autoimmune bullous conditions including Pemphigus and pemphigoid and other mast cell mediated skin disease.
Our analysis of this patent is as follows:
Glaxo Group Limited’s patent US 9447074 B2 deals with Compounds.
A compound of formula (I): or a salt thereof; which is an inhibitor of spleen tyrosine kinase (SYK) and therefore potential use in the treatment of diseases resulting from inappropriate activation of mast cells, macrophages, and B-cells and related inflammatory responses and tissue damage, for example inflammatory diseases and / or allergic conditions, in cancer therapy, especially heme malignancies, and autoimmune conditions.
The revolutionary TRAN&ASSOCIATES provides patent creation and management tools to help inventors protect their inventions using the patent system. Full lawyer support to complete and file the application is available.